De-escalation versus shortening of dual antiplatelet therapy

Eur Heart J Cardiovasc Pharmacother. 2024 Jul 16;10(4):267-269. doi: 10.1093/ehjcvp/pvae019.

Authors

Mattia Galli¹, Francesco Costa², Eliano Pio Navarese^{3

4}

Affiliations

¹ Maria Cecilia Hospital, GVM Care & Research, Via Corriera 1, 48033 Cotignola, RA, Italy.
² Department of Biomedical and Dental Sciences and Morphological and Functional Imaging, University of Messina, A.O.U. Policlinic 'G. Martino', Via Consolare Valeria 1, 98124 Messina, ME, Italy.
³ Clinical Experimental Cardiology, University of Sassari, Piazza Università 21, 07100, Sassari, SS, Italy.
⁴ SIRIO MEDICINE Research Network.

PMID: 38458235
DOI: 10.1093/ehjcvp/pvae019

No abstract available

Publication types

Letter

MeSH terms

Drug Administration Schedule
Dual Anti-Platelet Therapy* / adverse effects
Hemorrhage / chemically induced
Humans
Percutaneous Coronary Intervention / adverse effects
Platelet Aggregation Inhibitors* / administration & dosage
Platelet Aggregation Inhibitors* / adverse effects
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome

Substances

Platelet Aggregation Inhibitors